Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the growing number of patients with advanced liver disease will fuel a rise of the hepatitis C virus (HCV) market to $10 billion in 2013. HCV disease burden is expected to rise during the next ten years because of a maturing HCV population that has been infected for more than 20 years, the amount of time it takes for morbidity from HCV to emerge.

The new Pharmacor study entitled Hepatitis C Virus also finds that experts disagree about which patients are best suited for treatment given that HCV does not place all infected persons at risk of significant morbidity or mortality.

"Some experts contend that the goal of anti-HCV therapy is to prevent cirrhosis and hepatocellular carcinoma," says Jason LaBonte, Ph.D., analyst at Decision Resources. "Based on these criteria, patients with normal serum ALT levels and who therefore are not at risk of advanced liver disease do not require treatment. These experts also maintain that the safety and efficacy of current therapies is not sufficient to warrant treatment in this patient group. Other experts believe that patients with mild disease are more likey to respond to current therapies, and they say that the prevention of HCV transmission, improvement in quality of life, and improvement of symptoms are important considerations when determining whether or not to treat patients with normal serum ALT levels."

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Drug-Treated Diabetic Retinopathy Population to Quadruple by 2012

View Now